Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.

ABSTRACT:

SUBMITTER: Liu Z 

PROVIDER: S-EPMC9578965 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature